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Abstract
Cl-IB-MECA, synthetic A3 adenosine receptor agonist, is a potential anticancer agent. In this study, we have exam-
ined the effect of Cl-IB-MECA in a mouse melanoma model. Cl-IB-MECA significantly inhibited tumor growth in
immune-competent mice. Notably, the number of tumor-infiltrating NK1.1+ cells and CD8+ T cells was significantly
increased in Cl-IB-MECA–treated mice. This effect was correlated with high levels of tumor necrosis factor α (TNF-α)
and interferon γ in melanoma tissue. Depletion of either CD8+ T cells or NK1.1+ cells completely abrogated the
antitumor effect of Cl-IB-MECA. Accordingly, Cl-IB-MECA did not affect tumor growth in nude mice. In addition,
we also found that the number of mature and active conventional dendritic cells at the tumor site was increased
after Cl-IB-MECA administration. Moreover, Cl-IB-MECA significantly increased TNF-α and IL-12p40 release from
splenic CD11c+ cells. In conclusion, our study provides novel insights into the mechanism by which Cl-IB-MECA
leads to an effective antitumor response that involves the activation of natural killer cells and CD8+ T cells and fur-
ther highlights its therapeutic potential.
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Introduction
Skin melanoma is an aggressive tumor with high metastatic potential
and only a 5% 5-year survival rate [1]. The current scientific chal-
lenge is to overcome the resistance of melanoma to most chemother-
apeutics [2]. Accumulating evidence suggests that the activation of
both innate and adaptive immune systems can fight the overprolif-
eration of cancerous cells [3]. However, a major feature of melanoma
cells is their ability to escape immune surveillance through multiple
mechanisms, such as high production of immunosuppressive factors
that can impair immune cell function [4].
The adenosine system has the potential to modulate tumor growth.
In particular, adenosine is highly expressed under hypoxic conditions
observed in the tumor microenvironment [5]. Adenosine, through
binding to the A2A receptor, regulates the overall immune-suppressive
activity of immune cells through elevation of cyclic adenosine mono-
phosphate, which facilitates tumor growth [6–11]. Although the role
of A2A receptor on immune cells has been well characterized [12], the
effects of A3 receptor agonists are far less clear. A3 is an adenosine re-
ceptor subtype coupled to Gi/q protein, whose activation leads to the
reduction of cyclic adenosine monophosphate levels and phospholipase
C (PLC) activation.
It has been reported that A3R agonists (such as IB-MECA and Cl-
IB-MECA) are able to inhibit cancer cell proliferation in vitro and in
some in vivo tumor models (reviewed in Fishman et al. [13]). Our pre-
vious studies report that Cl-IB-MECA can downmodulate the phos-
phorylation of ERK1/2, induce G0/G1 cell cycle arrest and enhance
tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-
induced apoptosis in human thyroid cells [14,15]. However, A3R
agonists can concomitantly induce granulocyte colony-stimulating
factor production through nuclear factor-κB activation, preventing
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the myelotoxic effects of chemotherapy [13]. Furthermore, oral ad-
ministration of Cl-IB-MECA enhances the cytotoxic activity of
mouse natural killer (NK) cells and increases serum levels of inter-
leukin 12 (IL-12) in a mouse model of melanoma lung metastasis
and colon carcinoma [16,17]. Thus, in this study, we have further elu-
cidated the mechanism by which Cl-IB-MECA modulates tumor
growth in vivo. More specifically, we have investigated the immune-
modulatory effects of Cl-IB-MECA in melanoma-bearing mice.
Here, we demonstrate that Cl-IB-MECA inhibited the tumor
growth in an A3R-dependent manner. The systemic administration
of Cl-IB-MECA enhanced the presence of dendritic cells (DCs) and
NK cells in the tumor microenvironment. We also observed a strong
T-cell polarization toward a cytotoxic phenotype that promoted the re-
gression of melanoma lesions. The absence of NK1.1+ cells or CD8+
T cells attenuated Cl-IB-MECA–mediated inhibition of tumor growth.
These data suggest that Cl-IB-MECA can positively regulate the in-
duction of the innate and adaptive immunity against melanoma.
Materials and Methods
Cells
B16-F10 murine melanoma cell line was purchased from the Amer-
ican Type Culture Collection-LGC Standards S.r.e. (Milan, Italy) and
cultured in Dulbecco modified Eagle medium supplemented with
10% fetal bovine serum, L-glutamine (2 mM), penicillin (100 U/ml),
and streptomycin (10 U/ml) (Sigma-Aldrich, Milan, Italy).
Mice
Female C57Bl/6J and athymic Nude-Foxn1nu (6-8 weeks old)
were purchased from Harlan Laboratories (Udine, Italy) and main-
tained in a pathogen-free animal facility at the “Pascale” National
Cancer Institute according to institutional animal care guidelines,
Italian DL no. 116 of January 27, 1992, and European Communities
Council Directive of November 24, 1986 (86/609/ECC). For tumor
challenge, 2 × 105 B16-F10 cells were subcutaneously injected on the
right flank of anesthetized mice at day 0. At day 10, mice were intra-
peritoneally (i.p.) injected with Cl-IB-MECA (CIM, 0.1-1-10 μg/kg;
Tocris Cookson Ltd, London, UK) for three consecutive days (day 10-
11-12) and were killed on day 13. Tumor growth was monitored by
measuring the perpendicular diameters by means of a caliper (Stainless
Hardened; Ted Pella, Inc, Redding, CA) and calculated by the formula
4/3π × (long diameter / 2) × (short diameter / 2)2. At the end of each
treatment, mice were killed by cervical dislocation, and the tissues were
processed further.
In some experiments, MRS1191 (24 μg/kg, i.p.; K i = 31 nM;
Sigma-Aldrich) was coadministered with Cl-IB-MECA (1 μg/kg).
NK1.1+ or CD8+ T-cell depletion was performed by using functional-
grade purified antimouse NK1.1 (PK136; eBioscience, San Diego,
CA) [18] or antimouse CD8 (H37-17.2; eBioscience) [18] anti-
bodies, respectively, i.p. injected (100 μg/mouse) every 2 days (days
10 and 12) because these cells have a turnover of 3 to 4 days. In the
latter experiments, control mice received the respective control anti-
body (mouse IgG or rat IgG; eBioscience). The efficacy of depletion
was confirmed by flow cytometry analysis. We obtained complete de-
pletion of CD8+ T cells (90%) and 45% reduction of NK1.1+ cells,
respectively (data not shown).
Immunohistochemistry
Melanoma tissues were fixed in OCT medium (Ted Pella, Inc).
Sections of frozen tumor specimens (7 μm) were fixed with acetone,
permeabilized with methanol, and stained either with hematoxylin
and eosin (H&E staining) according to standard procedures or fur-
ther processed for immunofluorescence analysis. Frozen sections
were stained with specific antibodies for survivin (Santa Cruz Bio-
technology, DBA, Milan, Italy) or Ki67 (Dako, Cambridge, UK)
and detected with fluorescein isothiocyanate (FITC)– or phyco-
erythrin (PE)-labeled antimouse secondary antibodies, respectively
(eBioscience). In all staining experiments, isotype-matched IgG and
omission of the primary antibody was used as negative controls.
Apoptotic cells were detected using a kit from BioVision (Mountain
View, CA) to visualize DNA breaks as TUNEL+, according to the
manufacturer’s instructions. Slides were analyzed by using a fluores-
cence microscope (Carl Zeiss, Milan, Italy) by means of Axioplan
Imaging Program (Carl Zeiss).
BrdU Labeling
Mice were injected with BrdU (150 μg/mouse, Sigma Aldrich) i.p.
2 hours before sacrifice. Melanoma tissues were then removed, di-
gested, and stained with an FITC-labeled anti-BrdU antibody before
FACS analysis.
Flow Cytometry Analysis
Cell suspensions from tumors or spleen or tumor draining lymph
nodes (LNs) of treated mice were prepared for flow cytometric anal-
ysis 1(FACS). Freshly excised tissues were digested for 30 minutes at
37°C by collagenase A (1 U/ml). Cell suspensions were filtered
through a 40-μm nylon strainer, and red blood cells were lysed. Cells
were then labeled with the appropriate specific antibodies. Antibodies
used were against CD11c-FITC, CD11c-PE, CD11b-PeCy5.5, MHC
II-PE, CD80-PE, B220-PE, CD3-PeCy5.5 or PerCp, CD8-PE, and
NK1.1-PE (all eBioscience). Apoptotic cells were detected by com-
bined annexin V (AnxV)/propidium iodide (PI) staining using the
AnxV-FITC apoptosis detection kit (Bender Medsystem, Vienna,
Austria) according to the manufacturer’s instructions. The stained cells
were analyzed by using Becton Dickinson FACScan flow cytometer.
Isolation of Splenic DCs
CD11c-positive cells were isolated from spleens of naive C57Bl/6J
mice by using EasySep-positive selection kit according to the manu-
facturer’s instructions (Stem Cell Technologies, Koln, Germany).
The purity of the isolated CD11c+ cells was greater than 85% as as-
sessed directly by flow cytometry. CD11c+ cells were seeded and then
stimulated for 24 hours with CIM (20 nM–200 nM–2 μM) or ve-
hicle. Levels of tumor necrosis factor α (TNF-α), IL-6, IL-10, IL-12/
p40, and IL-23/p19 in the supernatants were assayed by using ELISA
kits (R&D System, Abingdon, UK, and eBioscience).
Enzyme-Linked Immunosorbent Assays
Serum and melanoma tissue homogenates levels of interferon γ
(IFN-γ), TNF-α, IL-6, IL-10, IL-12p40, and IL-23p40 were ana-
lyzed by ELISA kits (R&D Systems and eBioscience).
Analysis of RNA
Total tissue RNA was prepared using RNAspin Mini extraction
kit according to the manufacturer’s instructions (GE Healthcare,
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Milan, Italy). Reverse transcription was performed by using first-strand
complementary DNA synthesis kit (GE Healthcare) followed by
polymerase chain reaction. Thermal cycling conditions were 5 minutes
at 95°C, followed by 35 cycles of 45 seconds at 94°C, 20 seconds
at 58°C, and 30 seconds at 72°C. Primer pairs of A3R were as fol-
lows: forward 5′-GTTCCGTGGTCAGTTTGGAT-3′ and reverse
5′-GCGCAAACAAGAAGAGAACC-3′.
Statistical Analysis
Data were analyzed using Prism 4.0 (GraphPad Software, Inc, La Jolla,
CA). Results are expressed as mean ± SEM. All statistical differences were
evaluated by either two-tailed Student’s t test or one-way ANOVA fol-
lowed byDunnett post hoc analysis as appropriate. P < .05 was considered
statistically significant.
Results
Cl-IB-MECA Inhibits Melanoma Growth in Mice
We investigated the antitumor properties of Cl-IB-MECA in a mu-
rine melanoma model. C57Bl/6 mice were inoculated subcutaneously
onto the back with 2 × 105 B16-F10 cells/mouse at day 0 (Figure 1A).
Ten days after cell inoculation, melanoma-bearing mice were treated
i.p. with Cl-IB-MECA (CIM, 0.1-1-10 μg/kg) for three consecutive
days (days 10, 11, and 12) and then killed at day 13 (Figure 1A). The
administration of Cl-IB-MECA did not show any systemic toxic effect
in mice, such as drug-related death and body weight loss after CIM
administration (data not shown).
We found that Cl-IB-MECA treatment significantly inhibited tu-
mor growth in a dose-dependent manner compared with PBS-treated
mice, reaching a maximum suppression at 1 μg/kg (665.3 ± 142.3 vs
274.8 ± 69.45 Δ (mm3); Figure 1B). Histologic analyses (H&E
staining) of the tumor lesions showed that the presence of tumor
cells, visible as brown-spotted cells, was reduced when mice were
treated with Cl-IB-MECA (1 and 10 μg/kg) compared with PBS
(Figure 1C ). We examined the proliferative rate of tumor cells by
measuring the incorporation of BrdU in vivo. BrdU+ cells were sig-
nificantly lower in animals treated with both 1 and 10 μg/kg Cl-IB-
MECA compared with PBS-treated mice (Figure 1D). Furthermore,
the expression of Ki67, a tumor proliferation marker, was also re-
duced in melanoma tissue in Cl-IB-MECA–treated mice in a dose-
dependent manner (Figure 1E ).
Figure 1. CIM inhibits tumor growth in melanoma-bearing mice. (A) Experimental protocol: 10 days after B16-F10 cell implantation,
C57Bl/6 mice were treated (i.p.) with CIM (0.1-1-10 μg/kg) or PBS on days 10, 11, and 12, and mice were killed on day 13. (B) Tumor
volume was measured at days 10 and 13 and plotted as volume increase (Δmm3). At day 10, the tumor volume was 305.4 ± 82.48 mm3.
The tumor volume significantly increased between days 10 and 13 in PBS-treated mice. Administration of CIM significantly reduced
tumor volume compared with PBS (n = 20). Reduced cell proliferation was observed in CIM-treated mice as determined by represen-
tative H&E staining of melanoma tissue-derived cryosections (magnification, ×20; C), by reduced numbers of BrdU+ cells (D), and by
Ki67 by immunofluorescence staining (magnification, ×40; E). ns indicates not significant. Data shown are expressed as mean ± SEM.
Statistical differences were determined by one-way ANOVA followed by Dunnett post hoc analysis.
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Taken together, these results imply that Cl-IB-MECA can reduce
the tumor volume because of the inhibition of cancer cell prolifera-
tion. We then asked whether the inhibition of proliferation correlated
with apoptosis. The expression of survivin, an antiapoptotic and anti-
proliferative marker [19], was evaluated in melanoma tissue sections.
Treatment with Cl-IB-MECA reduced survivin staining in melanoma
cryosections compared with PBS (Figure W1A). The isotype control
(mouse IgG) did not show any positive staining. Cl-IB-MECA in-
creased the number of AnxV+/PI+ double-positive cells in melanoma
tissue, although not significantly (Figure W1B).
At this regard, we also performed TUNEL assay for signs of apop-
tosis on melanoma tissue section. In tumor sections harvested from
CIM-treated mice, we observed a marked increase in TUNEL+ cells
(with green nuclei) comparedwith control tumor section (FigureW1C).
One may therefore conclude that melanoma growth inhibition on
Cl-IB-MECA treatment was accomplished by apoptosis.
In addition, we examined whether Cl-IB-MECA (1 nM to 10 μM)
could directly affect B16-F10 tumor cells. There was no significant
effect of Cl-IB-MECA on cell viability or cell proliferation or apoptosis
rate at 24, 48, or 72 hours (Figure W2, A–C). This suggests that the
inhibition of tumor growth induced by Cl-IB-MECA in vivo cannot
be related to a direct cytotoxic effect on melanoma B16-F10 cells.
Cl-IB-MECA Antitumor Activity Is A3R Dependent
Cl-IB-MECA is a selective A3 adenosine receptor agonist. Reverse
transcription–polymerase chain reaction analysis showed that A3R was
expressed in melanoma tissue samples (Figure 2A). Because A3R
knockout mice, to our best knowledge, are not commercially available,
we used the selective A3R antagonist, MRS1191 (24 μg/kg) [20],
administered alone or in combination with Cl-IB-MECA (1 μg/kg).
MRS1191 significantly reversed the effect of Cl-IB-MECA on tumor
volume regression (Figure 2B, black bar vs open bar). The tumor
volume was not significantly altered in control mice treated with
MRS1191 alone compared with PBS (Figure 2B, black bar vs open
bar). The coadministration of MRS1191 also significantly reversed
the Cl-IB-MECA–induced reduction in BrdU+ cells (Figure 2C , black
bar vs open bar). These results showed that Cl-IB-MECA–induced in-
hibition of melanoma growth was A3R dependent.
Cl-IB-MECA Increases the Release of TNF-α and IFN-γ in
Melanoma Tissues
TNF-α and IFN-γ can induce tumor cell death [21]. We analyzed
the levels of TNF-α and IFN-γ in the serum and tumor tissue homog-
enates harvested from PBS- or Cl-IB-MECA–treated mice. TNF-α
levels were significantly increased at 1 and 10 μg/kg of Cl-IB-MECA
compared with PBS in tissue homogenates (Figure 3A), whereas no
significant changes in serum TNF-α were observed (Figure W3A).
Cl-IB-MECA administration also induced a significant dose-dependent
increase in the levels of IFN-γ in tissue homogenates compared with
PBS (Figure 3B). In addition, serum IFN-γ levels were significantly
higher in mice treated with 10 μg/kg Cl-IB-MECA (Figure W3B).
In contrast, serum levels of IL-6 and IL-10 were not affected by Cl-
IB-MECA treatment (Figure W3, C and D, respectively) and were
undetectable in the tissue homogenates.
NK Cells Are Essential for Cl-IB-MECA Antitumor Activity
TNF-α and IFN-γ play an important role in both innate and
acquired immunity [22] and are released from both NK cells and
CD8+ T cells [23–25]. Because Cl-IB-MECA increased both IFN-γ
and TNF-α expression in melanoma tissue, we asked whether the
Figure 2. The antitumor effect of CIM is reversed by the adenosine A3 receptor antagonist MRS1191. (A) A3R RNA expression on mel-
anoma tissue (lanes 1, 2, 3, and 4 indicate four different samples harvested from melanoma-bearing mice). (B) MRS1191 (24 μg/kg, black
bars) was administered by i.p. injection with PBS or CIM 1 μg/kg (n= 10). The effect of CIM on melanoma growth as measured by tumor
volume was significantly reversed by MRS1191. (C) MRS1191 significantly reversed the effect of CIM on the number of proliferative
(BrdU+) cells (n = 5). Data are expressed as mean ± SEM. Statistical differences were determined by Student’s t test.
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antitumor activity of Cl-IB-MECA was related to the activation of
the immune system. Cl-IB-MECA treatment significantly increased
melanoma-infiltrating NK1.1+ cell numbers in a dose-dependent manner
(Figure 4, A and B). NK cells were distinguished as CD11b+NK1.1high
and CD11b+NK1.1low, as observed in Figure 4A. Furthermore, de-
pletion of NK1.1+ cells completely abrogated the antitumor effect of
Cl-IB-MECA (1 μg/kg) (780.6 ± 208.6 vs 872.1 ± 226.1 Δ (mm3);
Figure 4C).
Moreover, a significant reduction in TNF-α and IFN-γ levels was
observed in tissue homogenates of Cl-IB-MECA + anti-NK1.1 Ab–
treated mice (black bars) when compared with Cl-IB-MECA + IgG
(open bars) (Figure 4, D and E , respectively). Taken together, these
Figure 3. CIM regulates the production of TNF-α and IFN-γ cytokines. CIM significantly increased the levels of TNF-α (n= 7) (A) and IFN-γ
(n = 9) (B) in melanoma tissue homogenates in a dose-dependent manner. Data are expressed as mean ± SEM. Statistical differences
were determined by one-way ANOVA followed by Dunnett post hoc analysis.
Figure 4. Analysis of the roleofNKcells onmelanomaafterCIMadministration.CIMsignificantly increased thenumberofCD11b+CD11c+NK1.1+
cells in melanoma tissue compared with PBS (n = 7). Representative plots are shown in A and mean data are depicted graphically in B.
(C) Depletion of NK1.1+ cells (black bars) completely blocked the antitumor effect of CIM (1 μg/kg) (n = 7). Depletion of NK1.1 cells (black bars)
attenuated CIM induction of TNF-α (D) and IFN-γ (E) levels in melanoma tissue homogenates (n = 7). All data are expressed as mean ± SEM.
Statistical differencesweredeterminedbyeither two-tailedStudent’s t test orone-wayANOVAfollowedbyDunnettposthocanalysis asappropriate.
Neoplasia Vol. 13, No. 4, 2011 Antitumor Activity of Cl-IB-MECA in Mice Morello et al. 369
data demonstrate that NK cells play an important role in the in vivo
antitumor activity of Cl-IB-MECA.
Cl-IB-MECA–Treated Mice Have Increased Infiltration of
DCs in Melanoma Tissues
NK cells can affect the development of adaptive immune response
[26,27]. Elevated levels of proinflammatory cytokines in the tumor
microenvironment can also affect the adaptive immune response, in-
cluding the antigen-presenting capacity of DCs and activation of
CD8+ T cells [28,29]. Cl-IB-MECA increased the number of tumor-
infiltratingCD11c+CD11b+myeloidDCs (mDCs) (Figure 5A). Impor-
tantly, Cl-IB-MECA enhanced mDC expression of both the MHC
class II maturation marker (Figure 5B) and the CD80 activation marker
(Figure 5C). These data suggest that melanoma-resident mDCs were
mature, active, and able to function as antigen-presenting cells.
We also assessed the effect of Cl-IB-MECA on DCs. We isolated
CD11c+ cells from the spleen of naive mice and treated them with
Cl-IB-MECA (20 nM–200 nM–2 μM) for 24 hours. We observed a
Figure 5. Tumor-infiltrating DCs are mature and active in mice treated with CIM. (A) The number of myeloid DCs (mDCs, CD11c+CD11b+
cells) significantly increased in melanoma tissue of mice treated with CIM compared with PBS (n = 5). Tumor-infiltrating mDCs were
mature and active as indicated by increased expression of the maturation marker MHC class II (B) and activation marker CD80 (C), respec-
tively (n = 5). Splenic CD11c+ cells isolated from naive mice and stimulated with CIM (20 nM–200 nM–2 μM) in vitro for 24 hours released
higher amounts of TNF-α (D) and IL-12p40 (E) than PBS-stimulated cells (n = 12). All data are expressed as mean ± SEM. Statistical differ-
ences were determined by one-way ANOVA followed by Dunnett post hoc analysis.
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significant increase in TNF-α and IL-12p40 (Figure 5, D and E , re-
spectively) but not IL-23p19 (data not shown) into the culture super-
natants of cells treated with Cl-IB-MECA compared with control.
Cl-IB-MECA antitumor Activity Is Mediated by CD8+ T Cells
BecauseDCs can directly regulate CD8+T cells [30], we next explored
whether the antitumor activity of Cl-IB-MECA could be mediated by
CD8+ T cells. Cl-IB-MECA induced a dose-dependent increase in the
number of tumor-infiltrating CD8+ T cells (Figure 6, A and B). In addi-
tion, the antitumor effect of Cl-IB-MECA (1 μg/kg) was significantly
attenuated in mice depleted of CD8+ T cells (809.5 ± 118.3 vs 188.5 ±
50.28 Δ (mm3); black bar vs open bar, Figure 6C). Furthermore, deple-
tion of CD8+ T cells also enhanced the tumor volume in PBS-treated
mice compared with control IgG-treatedmice (1271 ± 359.5 vs 561.7 ±
191.2 Δ (mm3); black bar vs open bar, Figure 6C ).
CD8+ T-cell depletion also significantly reduced melanoma tissue
levels of TNF-α and IFN-γ in Cl-IB-MECA–treated mice (black
bars vs open bars, Figure 6, D and E , respectively).
The antitumor ability of Cl-IB-MECA was also completely abro-
gated in athymic nu/nu (nude)mice (Figure 7A). In addition,melanoma
tissue levels of TNF-α and IFN-γ were very low after Cl-IB-MECA
administration in nude mice (Figure 7, B and C , respectively).
The number of apoptotic cells (AnxV+/PI+ cells) was extremely low
in melanoma-bearing nude mice (black bar) compared with the
C57Bl/6 mice (open bar) (0.77 ± 0.65 vs 2.73 ± 1.5) and even lower
in Cl-IB-MECA–treated nude mice (0.3 ± 0.2), but this was not sta-
tistically significant (Figure W4).
Discussion
In this study, we investigated the antitumor effect of Cl-IB-MECA.
We report that the activation of the immune system is essential for
the antitumor activity of Cl-IB-MECA. Specifically, there was an in-
creased recruitment of mature and active mDCs, NK, and CD8+
T cells into melanoma lesions after Cl-IB-MECA treatment. The de-
pletion of NK1.1+ cells or CD8+ T cells completely abrogated the
effect of Cl-IB-MECA in melanoma-bearing mice and blocked the
production of TNF-α and IFN-γ.
Adenosine is a ubiquitous nucleoside, which has a crucial role in
regulating multiple physiological responses, including inflammation
[6,31,32]. Adenosine is highly expressed by metabolically stressed
cells, such as cancerous cells [5,33]. Within the tumor microenviron-
ment, adenosine interferes with functions of immune cells, protect-
ing tumors from immune-mediated destruction [6,7]. These effects
Figure 6. The antitumor effect of CIM is mediated by CD8+ T cells. (A) CD3+CD8+ T cells were significantly increased in melanoma
tissues of mice treated with CIM compared with PBS (n = 10). (B) Representative FACS plots are shown in the right panel. (C) The
antitumor effects of CIM (1 μg/kg) was significantly reversed in CD8+ T-cell–depleted mice (black bar) compared with IgG controls (open
bar) (n = 7). Depletion of CD8+ T cells (black bars) significantly reduced CIM-induced TNF-α (D) and IFN-γ (E) expression in melanoma
tissue homogenates (n = 7). All data are expressed as mean ± SEM. Statistical differences were determined by either two-tailed Stu-
dent’s t test or one-way ANOVA followed by Dunnett post hoc analysis as appropriate.
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are mediated by the activation of A2A adenosine receptor, which has
the highest affinity for adenosine and is also upregulated on effector
T cells [11]. In contrast, A3 receptor agonists, such as Cl-IB-MECA,
enhance the cytotoxic activity of mouse NK cells and increase serum
levels of IL-12 in a mouse model of melanoma lung metastasis and
colon carcinoma [16,17]. This suggests that stimulation of the im-
mune system may underlie the antitumor effect of A3 receptor ago-
nists such as Cl-IB-MECA. Future studies using conditional A3R
knockout mice will enable confirmation of these results [37]. This
approach may also help determine whether the apparent loss of
CIM efficacy at 10 μg/kg compared with that observed at 1 μg/kg
is due to a loss of A3R selectivity or receptor desensitization.
In our mouse model, Cl-IB-MECA administration significantly
inhibited the proliferation of cancerous cells and increased the apop-
totic rate in melanoma lesions. Melanoma cells have low levels of
spontaneous apoptosis in vivo compared with other tumor cells
[2], and our in vitro studies on B16-F10 cells demonstrated that
Cl-IB-MECA was unable to directly inhibit cell proliferation or in-
duce apoptosis. It is possible, therefore, that the tumor growth inhi-
bition seen after Cl-IB-MECA administration may be induced by
changes in the immune environment leading to melanoma cell death.
IFN-γ can inhibit tumor cell growth and induce the differentia-
tion of NK and T cells into killer cells releasing TNF-α. Splenocytes
isolated from melanoma-bearing mice and stimulated ex vivo with
Cl-IB-MECA produced high levels of TNF-α compared with PBS
(data not shown), suggesting that Cl-IB-MECA may enhance the
cytotoxic activity of cells isolated from C57Bl/6 mice with mela-
noma. Our data show for the first time that CD8+ T cells mediate
the antitumor effect of Cl-IB-MECA. The functional relevance of
the latter cells in vivo was demonstrated using mice depleted of
CD8+ T cells and nude mice in which the activity of Cl-IB-MECA
against melanoma was impaired and the production of IFN-γ and
TNF-α in the tissue and serum was low.
Consistent with previous studies [16,17], we found that the inhi-
bition of tumor burden after Cl-IB-MECA treatment was correlated
with an increased cytotoxic activity of NK cells. In mice depleted of
NK1.1+ cells, the antitumor effect of Cl-IB-MECA was reversed and
associated with reduced tumor levels of TNF-α and IFN-γ, indicat-
ing that both NK and CD8+ T cells are major producers of these
cytokines. Further experiments using anti–TNF-α and/or anti–IFN-γ
will be necessary to determine whether these cytokines mediate the
functional effect of CIM in our tumor model.
Destruction of melanoma requires a complex interaction between
cancer cells and immunocompetent cells, including DCs and T cells
as well as cells of the innate immune system. DCs are usually imma-
ture in the tumor microenvironment because the low expression of
MHC class II and/or CD80/86 and IL-12 [34]. Immature DCs limit
T-cell activation and thus facilitate tumor progression [34]. In this
study, we showed that Cl-IB-MECA increased the number of ma-
ture and active DCs in melanoma lesions. Isolated splenic CD11c+
cells stimulated ex vivo with Cl-IB-MECA produced high levels of
IL-12 and TNF-α. However, activation of DCs is also mediated
Figure 7. Analysis of the antitumor effect of CIM in athymic nude (nu/nu) mice. (A) At day 10, the tumor volume in nude mice was 847.4 ±
180.2 mm3. CIM (0.1-1-10 μk/kg) administration did not affect tumor growth in Nu mice compared with PBS. TNF-α (B) and IFN-γ (C) levels
measured in the tissue homogenates harvested from PBS and CIM-treated Nu mice were extremely low. ns indicates not significant. Data
are expressed as mean ± SEM, n = 10. Statistical differences were determined by Student’s t test.
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by tissue-derived environmental factors and a variety of cells such as
NK and T cells [35,36].
In this respect, further in vitro studies will be needed to determine
whether the effect of Cl-IB-MECA is a direct effect on DCs or sub-
sequent to actions on NK or CD8+ T cells. The use of conditional
A3R knockouts will also enable further clarification of this issue [37].
In addition, extensive pharmacological and genetic studies will also
be required to elucidate the mediator(s) responsible for recruitment
of these various cells to the tumor in vivo.
In conclusion, our findings are the first demonstration that the A3
adenosine receptor agonist, Cl-IB-MECA, induces an efficient anti-
tumor immune response in melanoma-bearing mice. These results
further highlight the therapeutic potential of Cl-IB-MECA in cancer.
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Figure W1. CIM treatment increases apoptosis in melanoma tissue. (A) Survivin expression detected by immunofluorescence analy-
sis was reduced in CIM-treated mice compared with PBS. Data are representative of four independent experiments. Magnification,
×40. (B) The percentage of annexin V+ cells (left graph) and annexin V and PI double-positive cells (AnxV+/PI+) (right graph) in mice
treated with CIM (black bars) increased compared with PBS (open bar) (right panel). Representative dot plots are shown. Data are ex-
pressed as mean ± SEM (n = 7). (C) TUNEL+ staining (FITC) indicates apoptotic cells, which are increased in melanoma tissue har-
vested from mice treated with CIM compared with PBS. The pictures are representative of three experiments. Magnification, ×20.
Figure W2. Effect of Cl-IB-MECA on B16-F10 cells. Cl-IB-MECA (20 nM to 2 μM) was added to the B16-F10 cells in culture and cell
viability by MTT assay (A). Proliferation (B) and apoptosis (C) rates, by means of FACS analyses, were evaluated 24, 48, and 72 hours
later. Shown are the results obtained from cell cycle and apoptosis analyses at 24 hours; similar results were obtained at 48 hours. Data
are expressed as mean ± SEM (n = 6).
Figure W3. Serum levels of cytokines after CIM administration. Serum levels of TNF-α (n = 10; A), IL-6 (n = 13; C), and IL-10 (n = 13;
D) did not change after CIM treatment whereas levels of IFN-γ significantly increased at the highest dose of CIM compared with PBS
(n = 8) (B). Data are expressed as mean ± SEM. Statistical differences were determined by one-way ANOVA followed by Dunnett
post hoc analysis.
Figure W4. Apoptosis cells in nude melanoma-bearing mice after
CIM treatment. Apoptosis as determined by the number of annexin V
andpropidium iodide (PI) double-positive (AnxV+PI+) cellswas lower in
Nu mice treated with CIM (black bar) than those obtained in C57Bl/6
mice (open bar). Data are expressed as mean ± SEM, n = 10.
